I N T R O D U C T I O N
A reliable determination of renal function is fundamental in clinical practice and research. Glomerular filtration rate (GFR) can be estimated by formulas or measured with gold standard methods. Formulas are practical tools based on endogenous markers: creatinine, cystatin-C and variables like age, gender, race or weight. However, formulas do not reflect GFR with acceptable accuracy and precision, as indicated by studies in chronic kidney disease (CKD) [1, 2] , diabetes [3, 4] , renal transplantation [5, 6] , polycystic kidney disease [7] , cancer [8] , heart failure [9] , cirrhosis [10] , liver transplantation [11] and children with CKD [12] , among others. In general, the error of formulas is about 30% of measured GFR and this applies to both creatinine-and cystatin-C-based equations [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . This error limits the diagnosis of renal function [2, 3, 9, 10] , staging of CKD [6] and assessment of disease progression [1, 4, 5, 7] . The error of formulas also has consequences in clinical research, where estimated GFR decline can be either faster or slower than measured GFR decline [1, 4, 5, 7] . Therefore estimated GFR by formulas may generate misleading information on the effectiveness of new drugs to slow renal disease progression [13] .
Otherwise, gold standard methods to measure GFR include urinary or plasma clearance of inulin, 51 Cr-EDTA, 99 Tc-DTPA, V C The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. iothalamate or iohexol. These methods are reliable but cumbersome. For example, inulin clearance requires continuous intravenous infusion, bladder catheterization and urine collections [14] . Radio-labelled substances, i.e. 51Cr -EDTA, DTPA, require licensing and compliance with regulations for handling radioactive material [14] . The non-radioactive markers iothalamate and iohexol are considered more practical methods for GFR measurement [14] . However, the pre-analytical phase of these methods is still cumbersome and time consuming and so its use is restricted to research centres and specialized laboratories.
Therefore, clinical medicine stands at a crossroads: to rely on formulas that are practical but inaccurate or to consider gold standard techniques that are reliable but unpractical. Thus, a simple and reliable method to evaluate GFR is urgently needed.
In 1963, Robert Guthrie described the dried blood spot (DBS) analysis for the first time to detect phenylketonuria in neonates [15] . Since then, many studies have taken advantage of DBS to simplify the measurement of diverse analytes in biological matrixes. Few studies have evaluated the measurement of iohexol and GFR with DBS. However, these studies showed low accuracy and precision of the DBS compared with standard analysis [16, 17] . Thus, a reliable DBS technique to measure iohexol and GFR is not available. We developed a simple, accurate and precise method to measure iohexol and GFR using DBS testing.
M A T E R I A L S A N D M E T H O D S
For the development and validation of the measurement of iohexol in filter paper, we started with preliminary studies in vitro. Firstly, we tested the non-volumetric and volumetric DBS sampling approaches. Secondly, we performed the analytical validation recommended by the European Medicine Agency (EMA) guidelines [18] . Finally, the DBS method was validated in vivo in 203 patients with diverse degrees of renal function.
Preliminary studies in vitro
There is no evidence indicating which DBS sampling approach, volumetric or non-volumetric, is more reliable for measuring iohexol. So, we evaluated the agreement between both methods and the standard analysis in plasma.
Non-volumetric sampling approach. After finger-prick, the whole drop of blood is directly placed on filter paper (Whatman 903, GE Healthcare, Cardiff, UK). The quantity of dried blood in the DBS sample varies according to the volume of the drop. The blood is dried at room temperature overnight and then, a circle of filter paper (7.9 mm of diameter) is punched out with a special device (Ted Pella, INC., Redding, CA, USA). The DBS sample is partial, because the surface covered by the drop of blood is larger than the sample obtained for analysis ( Figure 1, upper panel) . For the preliminary studies in vitro, we simulated real drops with a variable volume of blood (30-40 mL) taken from the potassium ethylenediaminetretraacetic acid (K-EDTA) tubes with an automatic pipette and placed onto filter paper.
Volumetric sampling approach. A fixed volume is taken from the blood drop by a capillar pipette and deposited on filter paper. The quantity of blood in DBS sample is constant and the surface covered by blood is narrower than the piece of paper punched out for analysis (7.9 mm of diameter), thus, the whole volume of blood is analysed (Figure 1, lower panel) . For the preliminary studies in vitro, we took a fixed volume of blood (10 mL) from the EDTA-K tubes using a heparinized capillar pipette.
Procedures. We took advantage of 50 consecutive patients undergoing the plasma clearance of iohexol at our centre. On the day of the study, 5 mL of iohexol solution (Omnipaque 300, GE Healthcare) were injected intravenously during 2 min. For each patient, after iohexol injection, 3 mL of blood were collected in EDTA-K tubes at regular intervals: 120, 180, 240, 300, 360, 420 and 480 min (long protocol), for individuals with estimated [by abbreviated Modification of Diet in Renal Disease (aMDRD) formula] GFR 40 mL/min; or 120, 150, 180, 210 and 240 min (short protocol) for those with estimated GFR >40 mL/min [6] . Then, blood samples were taken from the tubes as indicated above to perform both sampling approaches. Finally, GFR was measured using iohexol concentrations determined by plasma analysis, volumetric DBS and non-volumetric DBS. The agreement between GFR determined with these methods was evaluated.
Sample preparation for DBS analysis. The extraction of iohexol from DBS samples is based on Niculescu-Duvaz et al. [16]. The sample is (i) placed in a tube with 250 mL of 5% perchloric acid; (ii) deproteinized by 3 min of vortex mixing; (iii) ultrasonicated for 15 min; (iv) incubated at room temperature for 30 min; and (v) centrifuged at 12 500 rpm for 10 min. No internal standard is used in this protocol.
To correct for possible errors during analysis, we modified the previous procedure by adding iopamidol as internal standard. Finally, we measured the clearance of iohexol as described above in a new group of 50 patients comparing the DBS method with internal standard and plasma analysis.
Iohexol determination for DBS analysis. In all, 25 mL of the supernatant of the DBS sample were analysed with a high performance liquid chromatography (HPLC) system Agilent series 1260 Infinity (Agilent Technologies, Santa Clara, CA, USA) equipped with a diode array detector set at 254 nm, and chromatographed by a C18 reverse phase column (5 lm, 150 Â 4.6 mm, Advanced Chromatography Technologies Ltd, Aberdeen, UK). Iohexol alone or iohexol and iopamidol [3 mg/mL in perchloric acid (5%)] were eluted using a mobile phase of deionized water (97%, adjusted to pH 2.5 with phosphoric acid) and acetonitrile (3%), pumped at a flow rate of 1.0 mL/min. GFR measurement. GFR was determined using iohexol concentrations measured in plasma and in DBS (volumetric and non-volumetric). GFR is calculated according to a onecompartment model (CL1) by the formula: CL1 ¼ Dose/AUC, where AUC is the area under the plasma concentration-time curve and corrected by the Bröchner-Mortensen formula:
To estimate the plasma levels of iohexol using DBS (volumetric and non-volumetric), blood iohexol concentrations were corrected according to haematocrit using the following formula: iox_pl ¼ iox_dbs/(1 -hto), where 'iox_pl' is the estimated plasma concentration of iohexol; 'iox_dbs' is the measured level of iohexol in DBS samples; and 'hto' is the haematocrit value of the patient.
Validation of the definitive DBS volumetric method in compliance with EMA guidelines
The selected DBS volumetric method (using iopamidol as internal standard) was tested in vitro before its implementation in vivo, in accordance with EMA guidelines [18] .
Studies in vivo
We compared GFR values obtained by the selected DBS approach and the reference method (plasma analysis) in 203 patients who underwent the plasma clearance of iohexol in our laboratory. Thus, simultaneously to every venous blood drawing for plasma analysis, we obtained capillary blood by finger-prick, which was deposited on filter paper. The agreement between GFR measured with plasma analysis and DBS testing was analysed.
Sample preparation for plasma analysis. The sample preparation for plasma analysis was based on Krutzén et al. with minor modification [20] . A total of 200 mL of the plasma samples were added to 50 mL of the internal standard: 1,3-dimethyluric acid (500 mg/mL in phosphate buffer, pH 7.4), and deproteinized by adding 750 mL of perchloric acid (5%), which is then subject to vortex mixing and centrifuging. Finally 5 mL of supernatant was analysed by an HPLC system with ultra violet detection (HPLC-UV).
Iohexol determination and GFR measurement. These procedures were the same as that described for the analysis in DBS in vitro.
Patients. In our centre, we use the plasma clearance of iohexol to measure renal function in clinical practice and research studies [6] . In 203 consecutive patients we performed simultaneously the plasma clearance of iohexol and the DBS method using capillary blood obtained by finger-prick. All patients signed an informed consent, and the study was approved by the Ethics and Clinical Research Committee of Hospital Universitario de Canarias.
Statistical analysis
The agreement between GFR values obtained with the reference method (plasma analysis) and DBS was assessed by the concordance correlation coefficient (CCC), total deviation index (TDI) and coverage probability (cp) [21] . CCC varies from 0 to 1, and a CCC >0.90 reflects optimal concordance between measurements. TDI captures a large proportion of data within a boundary for allowed differences between two measurements [21] . cp varies from 0 to 1 and it is a statistic that estimates whether a given TDI is less than a pre-specified fixed percentage. Empirical TDI was calculated for a theoretical TDI of 10% and a cp of 90%. We defined a priori that acceptable agreement between the reference and the DBS method should be a TDI <10%. This is based on the total variation of the method, which is 5-7% [22] . Agreement between the reference method (plasma analysis) and DBS technique was also evaluated by Bland-Altman limits of agreement [23] . We used the statistical package AGP (Agreement Program) v. 
R E S U L T S

Studies in vitro
Non-volumetric sampling method. GFR measured with iohexol concentrations determined in non-volumetric DBS had low CCC with GFR using plasma samples (reference method): CCC of 0.871 [0.742, lower 95% confidence interval (CI)] ( Table 1) . TDI of non-volumetric DBS was 26.0 (35.2, upper 95% CI), which means that 90% of the GFR values showed an error ranging from À26% to þ26% of the reference method (Table 1) . Finally, cp was 45.1 (30.3, lower 95% CI), which indicates that >55% of GFR values using DBS had an error greater than 610% of the plasma method (Table 1) . So, the non-volumetric method had low precision, accuracy and concordance, and was therefore rejected.
Volumetric sampling method. GFR determined with iohexol concentrations measured in volumetric DBS had a CCC of 0.971 (0.955, lower 95% CI) ( (Table 1) . Thus, the volumetric method showed better but insufficient agreement with the reference method.
Volumetric sampling method with an internal standard. TDI of 13% was greater than the 610% limit defined a priori to accept a new method. Thus, we decided to improve the volumetric method adding an internal standard to the chromatographic analysis. Iopamidol was tested and eluted as a single peak, had short retention time and excellent resolution and was therefore selected as the internal standard for DBS analysis. The introduction of iopamidol as internal standard improved the agreement between GFR using plasma and DBS: CCC was 0.993 (0.989, lower 95% CI), reflecting high precision and accuracy (Table 1) ; TDI was 9.0 (10.8, upper 95% CI), which means that 90% of the GFR values showed an error ranging from À9% to þ9% compared with the reference method (Table 1) . Finally, cp was 92.4 (85.7, lower 95% CI), which indicates that only 8% of the GFR values had an error range greater than 610% of the method in plasma (Table 1) . Therefore, the volumetric method using iopamidol as the internal standard was selected as the best choice for DBS analysis and was tested in vivo. Table 2 shows the results in 16 patients in whom GFR was determined by plasma analysis and the DBS methods. Nonvolumetric DBS showed a wide error, ranging from À11.9 to 27.6%. Volumetric DBS with method using internal standard showed an averaged error <10%.
Validation of the volumetric DBS method. The analytical validation of the volumetric DBS method based on the EMA guidelines is shown in Supplementary data. All the criteria defined in this guideline were fulfilled.
Studies in vivo
Patients. We included patients with diverse degrees of renal function, from advanced renal disease (GFR <30 mL/min) to normal renal function and hyperfiltration (GFR >120 mL/min) ( Table 3) . GFR values averaged 63.6 6 34.8 mL/min (9.1-159.7 mL/min) and 62.9 6 34.1 mL/min (9.7-164.6 mL/min) for the reference and DBS methods, respectively.
Agreement between GFR determineation with plasma samples and volumetric DBS. The agreement between GFR calculated with iohexol measured in plasma and DBS showed a CCC of 0.996 (0.995, lower 95% CI) ( Table 1) . TDI was 9.5 (10.5, upper 95% CI), and therefore 90% of the GFR values showed an error ranging from À9.5% to þ9.5% when compared with the reference method (plasma analysis) (Table 1) . Finally, cp was 91.0 (88.0, lower 95% CI) showing that 9% of the GFR values using DBS had an error greater than 610% of GFR using plasma analysis (Table 1) . Taken together, these results indicate excellent concordance, precision and accuracy between both methods. The Bland and Altman plot (Figure 2) showed an acceptable agreement between GFR values, with a mean difference (bias) of À0.7 mL/min and a 95% limit of agreement of À8.0 to 6.5 mL/min. 
D I S C U S S I O N
In this study, we simplified the plasma clearance of iohexol replacing plasma samples by capillary blood deposited in filter paper using DBS testing. In vitro and clinical validations showed acceptable agreement between plasma and volumetric DBS method. Thus, renal function can be measured by the plasma clearance of iohexol using DBS without losing accuracy and precision. This represents a major simplification of the measurement of renal function. Two different methods for DBS sampling have been described: non-volumetric and volumetric. For the former, whole drops of blood are placed directly on filter paper and a sample of this paper is punched-out including a partial quantity of blood (Figure 1, upper panel) . For the latter, a fixed volume of blood is taken from the drop with a capillary pipette and deposited on paper, which is completely included in the sample (Figure 1, lower panel) . We observed that the non-volumetric DBS was inaccurate and imprecise whereas the volumetric DBS had acceptable agreement with the reference method. The error of the non-volumetric DBS may be related to the variable volume of blood in the punched-out samples as a consequence of the different diffusion of blood through the paper, which is related to the haematocrit. Low haematocrit reduces blood viscosity, facilitating the blood diffusion and increasing the diameter of the blood spot. Conversely, high haematocrit increases blood viscosity, limiting its diffusion and reducing the diameter of the blood spot. For the non-volumetric DBS, it is assumed that the punched-out samples, which have a fixed diameter, contain the same volume of blood. However, the volume of blood (and the quantity of analytes) in the non-volumetric DBS samples is variable depending on the haematocrit and the different diffusion of blood on paper. This limitation reduces the precision and accuracy of the non-volumetric DBS method. This was probably the cause of the low agreement between plasma and DBS analyses in the studies of Niculescu-Duvaz et al. [16] and Salvador et al. [17] , which used the nonvolumetric DBS. The former observed wide limits of agreement, ranging from À13.9 to 16.2 mL/min for the DBS method using 3-spot samples. The latter reported wide limits of agreement ranging from À11.0 to 24.0 mL/min in children with CKD. Thus, the non-volumetric DBS must not be considered as a reliable method to measure iohexol and renal function.
On the other hand, the better performance of the volumetric method may be related to the collection of a fixed volume of blood that is completely included in the punched-out samples. To our knowledge, this is the first study that compares these two DBS methods for measuring iohexol and renal function.
To accept a new method, especially when one is a simplification of a gold standard, it is crucial to define a priori acceptable limits of agreement between both methods. The definition of acceptable agreement will depend on technical and clinical factors. For the case of the plasma clearance of iohexol, we defined tolerable limits of error between the reference and the DBS method as <10%. This criterion considers the total variation of the plasma clearance of iohexol that is about 5-7% [22] . Other studies used the non-volumetric DBS to measure diverse molecules [24] or accepted limits of agreement >10%. For example, Hoogtanders et al. considered acceptable a 614% of error for the measurement of tacrolimus [25] . However, the plasma clearance of iohexol is based on a pharmacokinetic curve, which requires high precision and accuracy. A deviation of a single point could greatly affect the calculation of the slope, the area under the curve and the value of GFR. This was the main reason for rejecting the non-volumetric DBS. This method led to an error of 626% of the standard analysis and to extreme variability of real renal function. The error of the non-volumetric method was clinically unacceptable, as shown in Table 2 .
The volumetric DBS showed better agreement with the standard method, TDI ¼ 13.0%, but still fell outside of the predefined limits of TDI <10%. We achieved acceptable agreement (TDI ¼ 9.5%) between plasma analysis and DBS with the use of an internal standard (iopamidol). The use of an internal standard is important in chromatography to correct and normalize possible errors during the analytical process. We used iopamidol as the internal standard for the volumetric DBS method, which showed a good chromatographic profile with good resolution and a suitable retention time for analysis.
A major strength of our study is the development of a clinical validation in subjects with an ample spectrum of renal function. The lack of clinical validation in DBS analysis has been previously indicated by Edelbroek et al. [24] . Notably, the TDI values of the volumetric DBS in vitro and in vivo were comparable, 9.0% vs 9.5%, which reflects the reliability of our results.
DBS testing has several advantages in comparison with conventional plasma analysis: (i) major improvement in patient comfort, since venopuntures are replaced by painless fingerprick. This is particularly important in cases with difficult venous access and in young children with renal disease; (ii) reduction in consumables like tubes, syringes, needles, etc.; (iii) avoidance of cold-storage facilities (fridges/freezers), since DBS can be safely stored at room temperature; (iv) increased safety, since viruses or bacteria lose the envelope during drying; and (v) simplification of shipment and transport regulations, because iohexol is stable at room temperature in DBS samples and can be sent by regular mail without the need of dry ice and special containers (Table 4) .
Our study has limitations. The method requires knowing the value of haematocrit. However, haematocrit is a standard and readily available analysis. Also, the collection of blood with a pipette must be accurate, avoiding incomplete filling or the presence of air bubbles inside the capillary pipette. Moreover, the whole volume of blood must be placed on paper. Nevertheless, a brief training is sufficient to achieve the correct procedure. Finally, there is not external quality control for iohexol measurement by DBS, which may limit the comparison between laboratories.
In conclusion, we simplified the plasma clearance of iohexol to measure renal function using DBS. The agreement between volumetric DBS testing and the reference method was acceptable, making both techniques interchangeable. The DBS method improves patient comfort, simplifies the pre-analytical phase and reduces the cost of the plasma clearance of iohexol.
The new volumetric DBS method may help to disseminate the measurement of renal function in clinical practice and research. 
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